National, regional, and state-level all-cause and cause-specific under-5 mortality in India in 2000-15: a systematic analysis with implications for the Sustainable Development Goals.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
06 2019
Historique:
received: 04 04 2018
revised: 07 02 2019
accepted: 13 02 2019
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 27 5 2020
Statut: ppublish

Résumé

India had the largest number of under-5 deaths of all countries in 2015, with substantial subnational disparities. We estimated national and subnational all-cause and cause-specific mortality among children younger than 5 years annually in 2000-15 in India to understand progress made and to consider implications for achieving the Sustainable Development Goal (SDG) child survival targets. We used a multicause model to estimate cause-specific mortality proportions in neonates and children aged 1-59 months at the state level, with causes of death grouped into pneumonia, diarrhoea, meningitis, injury, measles, congenital abnormalities, preterm birth complications, intrapartum-related events, and other causes. AIDS and malaria were estimated separately. The model was based on verbal autopsy studies representing more than 100 000 neonatal deaths globally and 16 962 deaths among children aged 1-59 months at the subnational level in India. By applying these proportions to all-cause deaths by state, we estimated cause-specific numbers of deaths and mortality rates at the state, regional, and national levels. In 2015, there were 25·121 million livebirths in India and 1·201 million under-5 deaths (under-5 mortality rate 47·81 per 1000 livebirths). 0·696 million (57·9%) of these deaths occurred in neonates. There were disparities in child mortality across states (from 9·7 deaths [Goa] to 73·1 deaths [Assam] per 1000 livebirths) and regions (from 29·7 deaths [the south] to 63·8 deaths [the northeast] per 1000 livebirths). Overall, the leading causes of under-5 deaths were preterm birth complications (0·330 million [95% uncertainty range 0·279-0·367]; 27·5% of under-5 deaths), pneumonia (0·191 million [0·168-0·219]; 15·9%), and intrapartum-related events (0·139 million [0·116-0·165]; 11·6%), with cause-of-death distributions varying across states and regions. In states with very high under-5 mortality, infectious-disease-related causes (pneumonia and diarrhoea) were among the three leading causes, whereas the three leading causes were all non-communicable in states with very low mortality. Most states had a slower decline in neonatal mortality than in mortality among children aged 1-59 months. Ten major states must accelerate progress to achieve the SDG under-5 mortality target, while 17 are not on track to meet the neonatal mortality target. Efforts to reduce vaccine-preventable deaths and to reduce geographical disparities should continue to maintain progress achieved in 2000-15. Enhanced policies and programmes are needed to accelerate mortality reduction in high-burden states and among neonates to achieve the SDG child survival targets in India by 2030. Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
India had the largest number of under-5 deaths of all countries in 2015, with substantial subnational disparities. We estimated national and subnational all-cause and cause-specific mortality among children younger than 5 years annually in 2000-15 in India to understand progress made and to consider implications for achieving the Sustainable Development Goal (SDG) child survival targets.
METHODS
We used a multicause model to estimate cause-specific mortality proportions in neonates and children aged 1-59 months at the state level, with causes of death grouped into pneumonia, diarrhoea, meningitis, injury, measles, congenital abnormalities, preterm birth complications, intrapartum-related events, and other causes. AIDS and malaria were estimated separately. The model was based on verbal autopsy studies representing more than 100 000 neonatal deaths globally and 16 962 deaths among children aged 1-59 months at the subnational level in India. By applying these proportions to all-cause deaths by state, we estimated cause-specific numbers of deaths and mortality rates at the state, regional, and national levels.
FINDINGS
In 2015, there were 25·121 million livebirths in India and 1·201 million under-5 deaths (under-5 mortality rate 47·81 per 1000 livebirths). 0·696 million (57·9%) of these deaths occurred in neonates. There were disparities in child mortality across states (from 9·7 deaths [Goa] to 73·1 deaths [Assam] per 1000 livebirths) and regions (from 29·7 deaths [the south] to 63·8 deaths [the northeast] per 1000 livebirths). Overall, the leading causes of under-5 deaths were preterm birth complications (0·330 million [95% uncertainty range 0·279-0·367]; 27·5% of under-5 deaths), pneumonia (0·191 million [0·168-0·219]; 15·9%), and intrapartum-related events (0·139 million [0·116-0·165]; 11·6%), with cause-of-death distributions varying across states and regions. In states with very high under-5 mortality, infectious-disease-related causes (pneumonia and diarrhoea) were among the three leading causes, whereas the three leading causes were all non-communicable in states with very low mortality. Most states had a slower decline in neonatal mortality than in mortality among children aged 1-59 months. Ten major states must accelerate progress to achieve the SDG under-5 mortality target, while 17 are not on track to meet the neonatal mortality target.
INTERPRETATION
Efforts to reduce vaccine-preventable deaths and to reduce geographical disparities should continue to maintain progress achieved in 2000-15. Enhanced policies and programmes are needed to accelerate mortality reduction in high-burden states and among neonates to achieve the SDG child survival targets in India by 2030.
FUNDING
Bill & Melinda Gates Foundation.

Identifiants

pubmed: 31097276
pii: S2214-109X(19)30080-4
doi: 10.1016/S2214-109X(19)30080-4
pmc: PMC6527517
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e721-e734

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Int J Epidemiol. 2006 Jun;35(3):706-18
pubmed: 16556647
J Biosoc Sci. 2008 Mar;40(2):183-201
pubmed: 18093346
Lancet. 2010 Jun 5;375(9730):1969-87
pubmed: 20466419
Int J Epidemiol. 2010 Aug;39(4):1103-14
pubmed: 20519334
Lancet. 2010 Nov 27;376(9755):1853-60
pubmed: 21075444
PLoS Med. 2011 Dec;8(12):e1001142
pubmed: 22205883
Lancet. 2012 Jun 9;379(9832):2151-61
pubmed: 22579125
Lancet. 2014 Dec 13;384(9960):2164-71
pubmed: 24793339
Lancet. 2014 Jul 12;384(9938):189-205
pubmed: 24853593
Lancet. 2014 Jul 26;384(9940):347-70
pubmed: 24853604
Lancet Glob Health. 2013 Oct;1(4):e219-26
pubmed: 25104347
Lancet. 2015 Jan 31;385(9966):430-40
pubmed: 25280870
J Health Popul Nutr. 2015 Mar;33(1):137-45
pubmed: 25995730
PLoS One. 2015 May 26;10(5):e0127105
pubmed: 26010084
J Glob Health. 2015 Dec;5(2):020408
pubmed: 26322230
Lancet. 2015 Dec 5;386(10010):2275-86
pubmed: 26361942
Semin Fetal Neonatal Med. 2015 Oct;20(5):315-20
pubmed: 26385051
J Glob Health. 2015 Dec;5(2):020409
pubmed: 26682045
Lancet. 2016 Dec 3;388(10061):2811-2824
pubmed: 27072119
PLoS Med. 2016 Jun 28;13(6):e1002056
pubmed: 27351744
Ann Appl Stat. 2015 Dec;9(4):1889-1905
pubmed: 27468328
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
J Perinatol. 2016 Dec;36(s3):S3-S8
pubmed: 27924104
J Perinatol. 2016 Dec;36(s3):S18-S23
pubmed: 27924106
J Perinatol. 2016 Dec;36(s3):S24-S31
pubmed: 27924107
J Perinatol. 2016 Dec;36(s3):S1-S2
pubmed: 27924108
J Perinatol. 2016 Dec;36(s3):S13-S17
pubmed: 27924109
Lancet Glob Health. 2017 Feb;5(2):e186-e197
pubmed: 28007477
BMC Health Serv Res. 2016 Oct 31;16(Suppl 6):561
pubmed: 28185593
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Lancet. 2017 Oct 28;390(10106):1972-1980
pubmed: 28939096
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376

Auteurs

Li Liu (L)

Department of Population Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Institute for International Programs, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: lliu26@jhu.edu.

Yue Chu (Y)

Institute for International Programs, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Shefali Oza (S)

Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Dan Hogan (D)

Health Metrics and Measurement Cluster, World Health Organization, Geneva, Switzerland.

Jamie Perin (J)

Institute for International Programs, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Diego G Bassani (DG)

Centre for Global Child Health, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Usha Ram (U)

Department of Public Health and Mortality Studies, International Institute for Population Sciences, Mumbai, India.

Shaza A Fadel (SA)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Arvind Pandey (A)

National Institute of Medical Statistics (Indian Council of Medical Research), New Delhi, India.

Neeraj Dhingra (N)

National Institute of Medical Statistics (Indian Council of Medical Research), New Delhi, India.

Damodar Sahu (D)

National Institute of Medical Statistics (Indian Council of Medical Research), New Delhi, India.

Pradeep Kumar (P)

National AIDS Control Organization, New Delhi, India.

Richard Cibulskis (R)

Global Malaria Programme, World Health Organization, Geneva, Switzerland.

Brian Wahl (B)

International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Anita Shet (A)

International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Colin Mathers (C)

Health Metrics and Measurement Cluster, World Health Organization, Geneva, Switzerland.

Joy Lawn (J)

Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Prabhat Jha (P)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Rakesh Kumar (R)

United Nations Development Programme, New Delhi, India.

Robert E Black (RE)

Institute for International Programs, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Simon Cousens (S)

Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH